AJMB2201 - CME/CMLE - Comparison of Anti–SARS-CoV-2 S1 Receptor-Binding Domain Antibody Immunoassays in Health Care Workers Before and After the BNT162b2 mRNA Vaccine-Comparison of Anti–SARS-CoV-2 S1 Receptor-Binding Domain Antibody Immunoassays in Health Care Workers Before and After the BNT162b2 mRNA Vaccine

Comparison of Anti–SARS-CoV-2 S1 Receptor-Binding Domain Antibody Immunoassays in Health Care Workers Before and After the BNT162b2 mRNA Vaccine

Back to course

Pdf Summary

The study evaluated the performance of new immunoassays in measuring antibodies against the receptor-binding domain (RBD) of the spike glycoprotein S1 in healthcare workers before and after receiving the BNT162b2 mRNA vaccine for SARS-CoV-2. Blood samples were collected from participants at various time points post-vaccination. The results showed a significant increase in antibody concentrations after vaccination with all methods. The study compared four immunoassays targeting RBD antibodies with one targeting N antibodies. It was observed that antibody concentrations rose post-vaccination with the RBD-targeting immunoassays detecting a strong response to the vaccine, whereas the N-targeting method failed to show a response. The study highlighted the importance of assessing antibody concentrations to monitor vaccine response and suggested the need for harmonizing units and cutoffs to improve agreement between methods. Additionally, the study indicated that post-vaccine immunity differed from that acquired through natural infection. The findings contribute to understanding vaccine-induced immunity and the significance of specific antibody responses. The study emphasized the role of serologic testing in vaccination strategies and post-vaccine monitoring. Further research may be needed to evaluate the performance of immunoassays with different vaccines and to assess antibody response in vaccinated individuals with previous SARS-CoV-2 infection.

Keywords

immunoassays

antibodies

receptor-binding domain

RBD

spike glycoprotein S1

BNT162b2 mRNA vaccine

SARS-CoV-2

vaccination

serologic testing

antibody response